For patients with an A1C of 6.5% to 7.5%, metformin is the preferred initial agent, with GLP-1 receptor agonists, dipeptidyl-peptidase-4 (DPP-4) inhibitors, thiazolidinediones (TZDs), or an alpha-glucosidase inhibitor listed as viable alternatives
These copays are significantly lower than commercial insurance or self-pay options, making TRICARE coverage a substantial benefit
By directly delivering essential nutrients, these treatments offer a powerful tool for enhancing energy levels, supporting weight management, and improving overall well-being
Complete biotransformation and protection from oxidative stress are important to maintaining cellular integrity and tissue health
More rarely, mutations in the genes CKDN1B, MAX, and SDHx variants could be seen